Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model

Cardiovascular Revascularization Medicine

Volumn 8, Issue 3, 2007, Pages 183-188

  Ayral, Yunus ^a   Rauch, Ursula ^a   Goldin Lang, Petra ^a   Stellbaum, Caroline ^a   Deiner, Carolin ^a   Schwimmbeck, Peter L ^b   Schultheiss, Heinz Peter ^a   Pels, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

Author keywords

C reactive protein; Clopidogrel; Inflammation; Percutaneous coronary intervention; Procoagulability

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL;

ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BLOOD CLOTTING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; INFLAMMATION; LOADING DRUG DOSE; MONOTHERAPY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOGENICITY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BLOOD COAGULATION; BRACHYTHERAPY; C-REACTIVE PROTEIN; INFLAMMATION; MODELS, ANIMAL; PLATELET AGGREGATION INHIBITORS; SUS SCROFA; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548226880     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2007.03.003     Document Type: Article

References (30)

1. Berglund U., and Richter A. Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. J Invasive Cardiol 14 5 (2002) 243-246
2. Holmes D. Antiplatelet therapy after percutaneous coronary intervention. Cerebrovasc Dis 21 Suppl 1 (2006) 25-34
3. Steinhubl S., Berger P., Mann J., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 19 (2002) 2411-2420
4. Chew D., Bhatt D., Robbins M., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88 6 (2001) 672-674
5. Klinkhardt U., Graff J., and Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 71 3 (2002) 176-185
6. Yaron G., Brill A., Dashevsky O., et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 134 4 (2006) 426-431
7. Navarro Estrada J., Gabay J., Alvarez J., et al. Relation of C-reactive protein to extent and complexity of coronary narrowing in patients with non-ST elevation acute coronary syndromes. A prospective cohort study. Coron Artery Dis 15 8 (2004) 477-484
8. Giesen P., Rauch U., Bohrmann B., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 96 5 (1999) 2311-2315
9. Rauch U., and Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 10 4 (2000) 139-143
10. Carson S., and Johnson D. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 76 2 (1990) 361-367
11. Hamilton K., Hattori R., Esmon C., and Sims P. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 265 7 (1990) 3809-3814
12. Kornowski R., Hong M., Tio F., Bramwell O., Wu H., and Leon M. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31 1 (1998) 224-230
13. Okamoto E., Couse T., De L., et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104 18 (2001) 2228-2235
14. Gottsauner-Wolf M., Zasmeta G., Hornykewycz S., et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 21 14 (2000) 1152-1158
15. Kuller L., Tracy R., Shaten J., and Meilahn E. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144 6 (1996) 537-547
16. Schillinger M., Mlekusch W., Wolfram R., et al. Endovascular brachytherapy: effect on acute inflammatory response after percutaneous femoropopliteal arterial interventions. Radiology 230 2 (2004) 556-560
17. 90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 106 9 (2002) 1090-1096
18. Waksman R., Raizner A., Yeung A., Lansky A., and Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 359 9306 (2002) 551-557
19. Jaster M., Fuster V., Rosenthal P., et al. Catheter based intracoronary brachytherapy leads to increased platelet activation. Heart 90 2 (2004) 160-164
20. Liistro F., Falsini G., Angioli P., Ducci K., and Bolognese L. Late acute thrombosis after implantation of sirolimus-eluting stent to treat in-stent restenosis. Acute Card Care 8 2 (2006) 116-118
21. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 7 (2003) 973-977
22. Versaci F., Gaspardone A., Tomai F., et al. Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 40 11 (2002) 1935-1942
23. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 82 4 (1998) 515-518
24. Zebrack J., Anderson J., Maycock C., Horne B., Bair T., and Muhlestein J. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 89 2 (2002) 145-149
25. Mehta S., Yusuf S., Peters R., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 9281 (2001) 527-533
26. Waksman R., Ajani A., Pinnow E., et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS4. Circulation 106 7 (2002) 776-778
27. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 6 (2004) 701-705
28. Lemos P., Serruys P., van Domburg R., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 2 (2004) 190-195
29. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 17 (2005) 2126-2130
30. Finkelstein A., Hausleiter J., Doherty T., et al. Intracoronary beta-irradiation enhances balloon-injury-induced tissue factor expression in the porcine injury model. Int J Cardiovasc Intervent 6 1 (2004) 20-27